E-ISSN 2146-9369 | ISSN 2146-3158
 
2024, Vol: 14, Issue: 4
14 / 4Current Issue ArchiveAims and ScopeAbstracting & IndexingMost Accessed ArticlesMost Downloaded ArticlesMost Cited Articles

Research Article 


Boosted- lopinavir versus boosted- atazanavir plus two nucleoside reverse transcriptase inhibitors in second- line antiretroviral therapy in HIV-1 infected patients in Abidjan (Ivory Coast)

Ehui Eboi, Kassi Indouba Alain, Kouakou Affoue Gisele, Mossou Melaine Chrysostome, Doumbia Adama, Ello Nogbou Frederic, Kamagate Sinaly, Koffi Tanon Aristophane, Eholie Serge Paul.


Abstract
Introduction: Atazanavir is a protease inhibitor recently introduce in the therapeutic arsenal for second-line antiretroviral therapy in Ivory Coast. The objective of this study was to compare the efficacy and safety of a second-line treatment with 2 NRTIs + boosted lopinavir (LPV/r) versus 2 NRTIs + boosted atazanavir (ATV/r) in HIV-1 positive patients in Abidjan.
Patients and Methods: Retrospective, comparative, single-center study, in 194 HIV-1 positive patients (143 with LPV/r, 51 with ATV/r), failed a first-line treatment, followed in Abidjan on 1 May 2009 to 30 June 2010. The analysis focused on clinical parameters and immuno-virological data. The principal judgement criterion was the proportion of patients with undetectable viral load in both groups after 12 months of HAART. Tolerance was found on the frequency of adverse events grade 3-4 during follow-up.
Results: Clinically, improvement of the general condition and regression of opportunistic infections was similar in both groups. The average gain of CD4 after 12 months of follow-up was +357/mm3 in the LPV/r group versus +278 mm3 for ATV/r group (p = 0.012). The percentage of patients with undetectable viral load was similar in both groups (92% vs. 96% ; p = 0.535). The frequency of grade 3-4 adverse events was similar in both groups.
Conclusion: HAART with LPV/r is at least as efficient as with ATV/r in second-line treatment, in terms of viral load reduction, with better recovery of CD4. LPV/r is an excellent second-line treatment in resource-limited countries. J Microbiol Infect Dis 2016;6(4): 149-156

Key words: Abidjan; Atazanavir; HIV; Lopinavir; Second-line; Sub-Saharan Africa


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Ehui Eboi
Articles by Kassi Indouba Alain
Articles by Kouakou Affoue Gisele
Articles by Mossou Melaine Chrysostome
Articles by Doumbia Adama
Articles by Ello Nogbou Frederic
Articles by Kamagate Sinaly
Articles by Koffi Tanon Aristophane
Articles by Eholie Serge Paul
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

Eboi E, Alain KI, Gisele KA, Chrysostome MM, Adama D, Frederic EN, Sinaly K, Aristophane KT, Paul ES. Boosted- lopinavir versus boosted- atazanavir plus two nucleoside reverse transcriptase inhibitors in second- line antiretroviral therapy in HIV-1 infected patients in Abidjan (Ivory Coast). J Microbiol Infect Dis. 2016; 6(4): 149-155 . doi:10.5799/jmid.328859

Web Style

Eboi E, Alain KI, Gisele KA, Chrysostome MM, Adama D, Frederic EN, Sinaly K, Aristophane KT, Paul ES. Boosted- lopinavir versus boosted- atazanavir plus two nucleoside reverse transcriptase inhibitors in second- line antiretroviral therapy in HIV-1 infected patients in Abidjan (Ivory Coast). https://www.jmidonline.org/?mno=302657017 [Access: January 09, 2025]. doi:10.5799/jmid.328859

AMA (American Medical Association) Style

Eboi E, Alain KI, Gisele KA, Chrysostome MM, Adama D, Frederic EN, Sinaly K, Aristophane KT, Paul ES. Boosted- lopinavir versus boosted- atazanavir plus two nucleoside reverse transcriptase inhibitors in second- line antiretroviral therapy in HIV-1 infected patients in Abidjan (Ivory Coast). J Microbiol Infect Dis. 2016; 6(4): 149-155 . doi:10.5799/jmid.328859


Vancouver/ICMJE Style

Eboi E, Alain KI, Gisele KA, Chrysostome MM, Adama D, Frederic EN, Sinaly K, Aristophane KT, Paul ES. Boosted- lopinavir versus boosted- atazanavir plus two nucleoside reverse transcriptase inhibitors in second- line antiretroviral therapy in HIV-1 infected patients in Abidjan (Ivory Coast). J Microbiol Infect Dis. (2016), [cited January 09, 2025]; 6(4): 149-155 . doi:10.5799/jmid.328859


Harvard Style

Eboi, E., Alain, . K. I., Gisele, . K. A., Chrysostome, . M. M., Adama, . D., Frederic, . E. N., Sinaly, . K., Aristophane, . K. T. & Paul, . E. S. (2016) Boosted- lopinavir versus boosted- atazanavir plus two nucleoside reverse transcriptase inhibitors in second- line antiretroviral therapy in HIV-1 infected patients in Abidjan (Ivory Coast). J Microbiol Infect Dis, 6 (4), 149-155 . doi:10.5799/jmid.328859


Turabian Style

Eboi, Ehui, Kassi Indouba Alain, Kouakou Affoue Gisele, Mossou Melaine Chrysostome, Doumbia Adama, Ello Nogbou Frederic, Kamagate Sinaly, Koffi Tanon Aristophane, and Eholie Serge Paul. 2016. Boosted- lopinavir versus boosted- atazanavir plus two nucleoside reverse transcriptase inhibitors in second- line antiretroviral therapy in HIV-1 infected patients in Abidjan (Ivory Coast). Journal of Microbiology and Infectious Diseases, 6 (4), 149-155 . doi:10.5799/jmid.328859


Chicago Style

Eboi, Ehui, Kassi Indouba Alain, Kouakou Affoue Gisele, Mossou Melaine Chrysostome, Doumbia Adama, Ello Nogbou Frederic, Kamagate Sinaly, Koffi Tanon Aristophane, and Eholie Serge Paul. "Boosted- lopinavir versus boosted- atazanavir plus two nucleoside reverse transcriptase inhibitors in second- line antiretroviral therapy in HIV-1 infected patients in Abidjan (Ivory Coast)." Journal of Microbiology and Infectious Diseases 6 (2016), 149-155 . doi:10.5799/jmid.328859


MLA (The Modern Language Association) Style

Eboi, Ehui, Kassi Indouba Alain, Kouakou Affoue Gisele, Mossou Melaine Chrysostome, Doumbia Adama, Ello Nogbou Frederic, Kamagate Sinaly, Koffi Tanon Aristophane, and Eholie Serge Paul. "Boosted- lopinavir versus boosted- atazanavir plus two nucleoside reverse transcriptase inhibitors in second- line antiretroviral therapy in HIV-1 infected patients in Abidjan (Ivory Coast)." Journal of Microbiology and Infectious Diseases 6.4 (2016), 149-155 . Print. doi:10.5799/jmid.328859


APA (American Psychological Association) Style

Eboi, E., Alain, . K. I., Gisele, . K. A., Chrysostome, . M. M., Adama, . D., Frederic, . E. N., Sinaly, . K., Aristophane, . K. T. & Paul, . E. S. (2016) Boosted- lopinavir versus boosted- atazanavir plus two nucleoside reverse transcriptase inhibitors in second- line antiretroviral therapy in HIV-1 infected patients in Abidjan (Ivory Coast). Journal of Microbiology and Infectious Diseases, 6 (4), 149-155 . doi:10.5799/jmid.328859


Author LoginReviewer LoginAbout PublisherOpen Access PolicyEditorial PoliciesPeer Review PolicyPublication Ethics and Publication Malpractice StatementConflict of Interest PolicyPlagiarism PolicyProtection of Research Participants (Statement On Human And Animal Rights)Privacy PolicyCorrections, Retractions & Expressions of ConcernSelf-Archiving PoliciesDigital Archiving & Preservation PoliciesStatement of Informed ConsentAdvertising PolicyTerms of UseLicense InformationCopyright Information

About Journal of Microbiology and Infectious Diseases

Journal of Microbiology and Infectious Diseases (JMID) is an international "peer review" journal in microbiology, infectious diseases, virology, ... Read more.



For best results, please use Internet Explorer or Google Chrome.

Contact Information

All correspondence should be addressed to:

Prof. Ibrahim Eldaghayes

Editor-in-Chief

Journal of Microbiology and Infectious Diseases

Department of Microbiology and Parasitology 

Faculty of Veterinary Medicine

University of Tripoli

P.O. Box 13662, Tripoli, Libya